Janelle Hart
Managing Editor, Custom Content
Latest From Janelle Hart
Secarna Addresses Undruggable Targets With Antisense Platform
At the 2024 BIO International Convention, In Vivo spoke with Secarna Pharmaceuticals' CEO Alexander Gebauer about how the biotech's next-gen antisense oligonucleotide technology aims to benefit patients across multiple indications.
How Cellino’s Cassette Technology Will Impact Regenerative Medicine
Co-founder and CEO of Cellino Biotech, Nabiha Saklayen, discusses the company’s innovative platform which uses automated technologies to overcome challenges in the development of regenerative medicine.
Cutiss’ Approach To Skin Engineering
CUTISS co-founder and CEO Daniela Marino shares insights with In Vivo about the future of regenerative medicine and the ongoing development of denovoSkin, a next-generation human skin graft technology.
Next-Gen ADCs: Araris CEO Highlights Potential In Linker Technology
In Vivo sat down with 2023 Rising Leader Philipp Spycher, CEO of Araris Biotech, to discuss trends in antibody-drug conjugate R&D, and how Araris hopes to disrupt today’s chemotherapy treatment paradigm with novel linker technology.
Exploring Alltrna’s Rare Disease Platform
Michelle Werner, CEO of Alltrna, sat down with In Vivo to discuss rare disease as an increasingly important area of study, innovation in the space and how the emerging biotech hopes to impact the treatment landscape.